Agenus (NASDAQ:AGEN) Analyst Rating Consensus

Agenus (NASDAQ:AGEN) has received a short term rating of sell from experts at Zacks with a rank of 4. The stock has been rated an average of 1 by 5 Brokerage Firm. 5 Wall Street Firms have rated the stock as a strong buys.

Other Equity analysts have also commented on the company shares. Maxim Group upgrades its view on Agenus (NASDAQ:AGEN) according to the research report released by the firm to its investors. The shares have now been rated Buy by the stock experts at the ratings house. Earlier, the shares had a rating of Hold. Maxim Group announces the current price target of $7 per share on Agenus . The rating by the firm was issued on March 11, 2016.

Agenus (NASDAQ:AGEN) should head towards $9.25 per share according to 4 Analysts in consensus. However, if the road gets shaky, the stock may fall short to $6 per share. The higher price estimate target is at $14 according to the Analysts.

Agenus (NASDAQ:AGEN) witnessed a decline in the market cap on Tuesday as its shares dropped 2.37% or 0.1 points. After the session commenced at $4.24, the stock reached the higher end at $4.26 while it hit a low of $4.06. With the volume soaring to 1,342,386 shares, the last trade was called at $4.12. The company has a 52-week high of $9.64. The company has a market cap of $358 million and there are 86,882,451 shares in outstanding. The 52-week low of the share price is $2.61.

Shares of Agenus Inc. rose by 5.37% in the last five trading days and 12.88% for the last 4 weeks. Agenus Inc. has dropped 0.72% during the last 3-month period . Year-to-Date the stock performance stands at -9.25%.

Agenus Inc. (Agenus) is an immunotherapy company. The Company is engaged in discovering and developing treatments for patients with cancer and other diseases. Its approaches are driven by three platform technologies: Its antibody platform, including Retrocyte Display technology, which is designed to produce human monoclonal antibodies focused on advancing checkpoint modulators (CPMs); its heat shock protein (HSP)-based vaccines, and its saponin-based vaccine adjuvants, QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company has a portfolio of programs in pre-clinical and clinical stages, including a series of CPMs in investigational new drug (IND)-enabling studies, Prophage Series vaccine, a Phase III ready HSP-based autologous vaccine for glioblastoma multiforme (GBM), which is a form of brain cancer, and a number of QS-21 Stimulon-containing vaccine candidates in late stage development by its partner, GlaxoSmithKline (GSK).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *